MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail) - Kite Pharma, Inc. - Collaboration And License Agreement $ in Millions	1 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Apr. 30, 2018 USD ($) milestone	Sep. 30, 2021 USD ($) option	Dec. 31, 2020 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received		$ 150.0
Development and sales-based milestone payments to be received		3,010.0
Initial research term of agreement			6 years
Number of options to extend initial research term | option			2
Extended research term of agreement			1 year
Separate upfront fee			$ 10.0
Collaborative arrangement estimated reimbursable service costs for new research plan	$ 3.4
Collaborative arrangement transaction price	$ 189.3
Revenues under agreement			150.0
Collaborative arrangement estimated reimbursable service costs			39.3
Deferred revenue			$ 62.8	$ 81.4
Achievement of specified research, clinical development, regulatory and first commercial sale milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development - and sales-based milestone payments to be received		1,260.0
Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development - and sales-based milestone payments to be received		$ 1,750.0
Maximum amount of achieved milestones to receive payment | milestone		10